Andrea Lobo,  —

Components from tire wear, higher temperatures and age accelerate the degeneration of dopaminergic neurons in Parkinson’s disease, a new study done in nematode worms suggests. The study, “Tire components, age and temperature accelerate neurodegeneration in C. elegans models of Alzheimer’s and Parkinson’s disease,” was published in the journal…

A collaborative effort between the University of Oxford and Selvita will foster the development of potential disease-modifying therapies targeting alpha-synuclein aggregation, a key hallmark of Parkinson’s disease. The accumulation of toxic aggregates of alpha-synuclein contributes to the progressive loss of dopaminergic neurons, the nerve cells in the…

Neuronic has partnered with Santa Clara University in Silicon Valley to develop a research project to study light therapy guided by real-time brain activity. Light therapy, also called photobiomodulation, is painless and noninvasive, and uses light-emitting diodes (LEDs) to deliver near-infrared light that passes through the skin and…

h2o Therapeutics has partnered with AmerisourceBergen to commercialize Parky, a prescription mobile app that monitors symptoms in people with Parkinson’s disease, such as tremors and involuntary muscle movements. The Parky app monitors a patients’ symptoms in real time using an Apple Watch, and shares the data…

Sinopia Biosciences has selected SB-0110 as its lead clinical candidate for Parkinson’s disease after extensive preclinical studies. The move has triggered a cumulative funding of $3.3 million of its fast-track Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke. The fast-track SBIR…

The first healthy volunteer has been dosed in a clinical study that will test the safety and efficacy of Herantis Pharma’s HER-096 treatment candidate for Parkinson’s disease, the company announced in a press release. The Phase 1a clinical trial also is evaluating the ability of HER-096 to penetrate…

NeuroPoint Alliance’s (NPA) registry for people with Parkinson’s disease eligible for deep brain stimulation (DBS) surgery announced that it has completed its initial pilot phase, collecting information on more than 170 patients who underwent the treatment. Called the Registry for the Advancement of DBS in Parkinson’s Disease, or…

Heavier coffee drinkers, based on the number of cups consumed daily, have a lower volume of the striatum, a brain region affected in Parkinson’s disease, whether or not they have Parkinson’s, a study from China using MRI data reported. Regular coffee consumption, without an emphasis on cups per day,…

Women with Parkinson’s disease are less likely to be referred for deep brain stimulation (DBS) evaluation than men, a study has found. Moreover, women with essential tremor, a disease that shares symptoms with Parkinson’s and can also be treated with DBS, were more likely to decline surgery, once approved.

Home initiation of under-the-skin (subcutaneous) apomorphine infusion — a treatment for motor fluctuations — is faster at improving the life quality of Parkinson’s disease patients than in hospital initiation, a French study has shown. Continuous subcutaneous apomorphine infusion (CSAI) initiation at home for Parkinson’s was found to be feasible…